GB201417094D0 - Novel compounds - Google Patents

Novel compounds

Info

Publication number
GB201417094D0
GB201417094D0 GBGB1417094.8A GB201417094A GB201417094D0 GB 201417094 D0 GB201417094 D0 GB 201417094D0 GB 201417094 A GB201417094 A GB 201417094A GB 201417094 D0 GB201417094 D0 GB 201417094D0
Authority
GB
United Kingdom
Prior art keywords
novel compounds
compounds
novel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1417094.8A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Intellectual Property Development Ltd
Original Assignee
GlaxoSmithKline Intellectual Property Development Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Intellectual Property Development Ltd filed Critical GlaxoSmithKline Intellectual Property Development Ltd
Priority to GBGB1417094.8A priority Critical patent/GB201417094D0/en
Publication of GB201417094D0 publication Critical patent/GB201417094D0/en
Application status is Ceased legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002Heterocyclic compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05Isotopically modified compounds, e.g. labelled
GBGB1417094.8A 2014-09-26 2014-09-26 Novel compounds Ceased GB201417094D0 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GBGB1417094.8A GB201417094D0 (en) 2014-09-26 2014-09-26 Novel compounds

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
GBGB1417094.8A GB201417094D0 (en) 2014-09-26 2014-09-26 Novel compounds
JP2017516367A JP2017528504A (en) 2014-09-26 2015-09-22 Naphthyridine derivatives as αvβ6 integrin antagonists for the treatment of such fibrotic diseases
EP15767478.9A EP3197894A1 (en) 2014-09-26 2015-09-22 Naphthyridine derivatives as alpha v beta 6 integrin antagonists for the treatment of e.g. fibrotic diseases
CN201580052204.2A CN107074851A (en) 2014-09-26 2015-09-22 Naphthyridine derivatives as alpha v beta 6 integrin antagonists for the treatment of e.g. fibrotic diseases
BR112017006242A BR112017006242A2 (en) 2014-09-26 2015-09-22 naphthyridine derivatives as antagonists of integrin alpha v beta 6 for the treatment of, e.g., fibrotic diseases
US15/514,416 US10144733B2 (en) 2014-09-26 2015-09-22 Naphthyridine derivatives as alpha v beta 6 integrin antagonists for the treatment of E.G. fibrotic diseases
AU2015320863A AU2015320863B2 (en) 2014-09-26 2015-09-22 Naphthyridine derivatives as alpha v beta 6 integrin antagonists for the treatment of e.g. fibrotic diseases
RU2017114355A RU2017114355A3 (en) 2014-09-26 2015-09-22
CA2962321A CA2962321A1 (en) 2014-09-26 2015-09-22 Naphthyridine derivatives as alpha v beta 6 integrin antagonists for the treatment of e.g. fibrotic diseases
KR1020177007736A KR20170053638A (en) 2014-09-26 2015-09-22 Naphthyridine derivatives as alpha v beta 6 integrin antagonists for the treatment of e.g. fibrotic diseases
PCT/EP2015/071782 WO2016046230A1 (en) 2014-09-26 2015-09-22 Naphthyridine derivatives as alpha v beta 6 integrin antagonists for the treatment of e.g. fibrotic diseases
US16/165,506 US20190048005A1 (en) 2014-09-26 2018-10-19 Naphthyridine derivatives as alpha v beta 6 integrin antagonists for the treatment of e.g. fibrotic diseases

Publications (1)

Publication Number Publication Date
GB201417094D0 true GB201417094D0 (en) 2014-11-12

Family

ID=51901231

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1417094.8A Ceased GB201417094D0 (en) 2014-09-26 2014-09-26 Novel compounds

Country Status (11)

Country Link
US (2) US10144733B2 (en)
EP (1) EP3197894A1 (en)
JP (1) JP2017528504A (en)
KR (1) KR20170053638A (en)
CN (1) CN107074851A (en)
AU (1) AU2015320863B2 (en)
BR (1) BR112017006242A2 (en)
CA (1) CA2962321A1 (en)
GB (1) GB201417094D0 (en)
RU (1) RU2017114355A3 (en)
WO (1) WO2016046230A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201305668D0 (en) 2013-03-28 2013-05-15 Glaxosmithkline Ip Dev Ltd Avs6 Integrin Antagonists
GB201417002D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compound
GB201417011D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417018D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
BR112018068638A2 (en) 2016-03-15 2019-02-05 Bayer Cropscience Ag substituted sulfonamides for controlling animal pests
WO2018089357A1 (en) 2016-11-08 2018-05-17 Bristol-Myers Squibb Company INDAZOLE DERIVATIVES AS αV INTEGRIN ANTAGONISTS
WO2018089358A1 (en) 2016-11-08 2018-05-17 Bristol-Myers Squibb Company Azole amides and amines as alpha v integrin inhibitors
WO2018089353A1 (en) 2016-11-08 2018-05-17 Bristol-Myers Squibb Company 3-substituted propionic acids as alpha v integrin inhibitors
WO2018089360A1 (en) 2016-11-08 2018-05-17 Bristol-Myers Squibb Company Pyrrole amides as alpha v integrin inhibitors
TW201819378A (en) 2016-11-08 2018-06-01 Squibb Bristol Myers Co Cyclobutane- and azetidine-containing mono and spirocyclic compounds as [alpha]v integrin inhibitors

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EE200000362A (en) 1997-12-17 2001-12-17 Merck & Co., Inc. Integrin receptor antagonists, pharmaceutical composition and method of manufacture
AU736026B2 (en) 1997-12-17 2001-07-26 Merck & Co., Inc. Integrin receptor antagonists
WO2000072801A2 (en) 1999-06-02 2000-12-07 Merck & Co., Inc. Alpha v integrin receptor antagonists
AU748949B2 (en) 1999-06-23 2002-06-13 Merck & Co., Inc. Integrin receptor antagonists
AU7743400A (en) * 1999-10-04 2001-05-10 Merck & Co., Inc. Integrin receptor antagonists
CN1414966A (en) 1999-11-08 2003-04-30 麦克公司 Process and intermediates for preparation of imidazolidinone alpha U protein antagonists
US6933304B2 (en) 2000-06-15 2005-08-23 Pharmacia Corporation Heteroarylalkanoic acids as integrin receptor antagonists
AU7793501A (en) 2000-07-26 2002-02-05 Merck & Co Inc Alpha v integrin receptor antagonists
AU9077201A (en) 2000-09-14 2002-03-26 Merck & Co Inc Alpha v integrin receptor antagonists
EP1349548A4 (en) 2001-01-03 2004-06-02 Merck & Co Inc Methods and compositions for treating periodontal disease
DE10112771A1 (en) 2001-03-16 2002-09-26 Merck Patent Gmbh New 3-acylamino-3-phenyl-propionic acid derivatives, are integrin inhibitors useful e.g. for treating thrombosis, cardiac infarction, angina pectoris, tumor diseases, inflammation, osteoporosis or infections
US20040224986A1 (en) 2002-08-16 2004-11-11 Bart De Corte Piperidinyl targeting compounds that selectively bind integrins
BR0317600A (en) 2002-12-20 2005-11-29 Pharmacia Corp heteroarilalcanóicos acid derivatives as integrin receptor antagonists
US6932865B2 (en) 2003-04-11 2005-08-23 Lockheed Martin Corporation System and method of making single-crystal structures through free-form fabrication techniques
WO2008118455A1 (en) 2007-03-23 2008-10-02 Amgen Inc. δ3- SUBSTITUTED QUINOLINE OR QUINOXALINE DERIVATIVES AND THEIR USE AS PHOSPHATIDYLINOSITOL 3-KINASE ( PI3K) INHIBITORS
WO2009055418A1 (en) 2007-10-22 2009-04-30 Smithkline Beecham Corporation Pyridosulfonamide derivatives as pi3 kinase inhibitors
WO2011111880A1 (en) 2010-03-08 2011-09-15 주식회사 메디젠텍 Pharmaceutical composition for treating or preventing diseases caused by the nuclear export of gsk3, including a compound for inhibiting the nuclear export of gsk3
GB201305668D0 (en) * 2013-03-28 2013-05-15 Glaxosmithkline Ip Dev Ltd Avs6 Integrin Antagonists
AU2014324426A1 (en) 2013-09-30 2016-04-21 The Regents Of The University Of California Anti-alphavbeta1 integrin compounds and methods
GB201417011D0 (en) * 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417018D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417002D0 (en) * 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compound
US9790222B2 (en) 2015-02-19 2017-10-17 Scifluor Life Sciences, Inc. Fluorinated tetrahydronaphthyridinyl nonanoic acid derivatives and uses thereof
JP2018515424A (en) 2015-03-10 2018-06-14 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Anti-alpha v beta 1 integrin inhibitors and methods of use
GB201604589D0 (en) 2016-03-18 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical compound
GB201604681D0 (en) 2016-03-21 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical Compounds
GB201604680D0 (en) 2016-03-21 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical Compounds

Also Published As

Publication number Publication date
US20170291899A1 (en) 2017-10-12
AU2015320863A1 (en) 2017-03-09
EP3197894A1 (en) 2017-08-02
US10144733B2 (en) 2018-12-04
RU2017114355A (en) 2018-10-29
RU2017114355A3 (en) 2019-01-14
AU2015320863B2 (en) 2018-09-06
JP2017528504A (en) 2017-09-28
CN107074851A (en) 2017-08-18
WO2016046230A1 (en) 2016-03-31
BR112017006242A2 (en) 2017-12-12
CA2962321A1 (en) 2016-03-31
KR20170053638A (en) 2017-05-16
US20190048005A1 (en) 2019-02-14

Similar Documents

Publication Publication Date Title
HK1217861A1 (en) Wifi-coordinated laa-lte
GB201416754D0 (en) Novel compounds
GB201501462D0 (en) Novel compounds
GB201417002D0 (en) Novel compound
GB201410907D0 (en) No details
GB201417011D0 (en) Novel compounds
GB201417094D0 (en) Novel compounds
GB201404893D0 (en) Selfie - Stick
SG11201605342UA (en) Compounds
GB201402431D0 (en) Compounds
TWI582083B (en) Aminopyridyloxypyrazole compounds
TWI583681B (en) Aminopyrimidinyl compounds
GB201417018D0 (en) Novel compounds
GB201418300D0 (en) Compounds
EP3325449A4 (en) Compounds
GB201419094D0 (en) Anti-TIM-3-antibodies
GB201418217D0 (en) No details
GB201506871D0 (en) Novel compounds
GB201404498D0 (en) New compounds
GB201409044D0 (en) New compounds
GB201410430D0 (en) Compounds
SG11201606693SA (en) Novel compounds
SG11201609722UA (en) Novel compounds
GB2529896B (en) Multirotor
GB2528557B (en) Soundbar

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)